Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imidafenacin vs Fesoterodine in Overactive Bladder
NCT01578304Phase 4Completed
- Sponsor
- LG Chem
- Start
- Dec 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of imidafenacin in overactive bladder (OAB) (2 arms), sponsored by LG Chem. Primary endpoint: Difference in daily mean urination frequency at 12 weeks. Started Dec 2010; status: completed.
02
Drugs
imidafenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT01578304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01578304.